Unicycive Therapeutics, Inc. Common Stock
Symbol: UNCY (NASDAQ)
4.32
▲ (3.98%) 0.165
Company Description:
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Key Stats
- Today's Open: $4.13
- Today's High: $4.35
- Today's Low: $4.115
- Today's Volume: 448.54K
- Yesterday Close: $4.15
- Yesterday High: $4.28
- Yesterday Low: $3.97
- Yesterday Volume: 620.32K
- Last Min Volume: 0
- Last Min High: $4.315
- Last Min Low: $4.302
- Last Min VWAP: $0
Company Profile
- Name: Unicycive Therapeutics, Inc. Common Stock
- Website: https://www.unicycive.com
- Listed Date: 2021-07-13
- Location: LOS ALTOS, CA
- Market Status: Active
- CIK Number: 0001766140
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $73.30M
- Round Lot: 100
- Outstanding Shares: 17.66M
- Asset Type: CS
RECENT FILINGS FOR UNCY
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-26 | 4 | View |
| 2025-08-18 | 8-K | View |
| 2025-08-15 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 8-K | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-30 | 4 | View |
| 2025-07-08 | 8-K | View |
| 2025-06-30 | 8-K | View |
| 2025-06-20 | 8-K | View |
| 2025-06-13 | 424B5 | View |
Latest News on UNCY